◀ Back to EPHB2

EPHB2 — SLPI

Text-mined interactions from Literome

Ruiter et al., Int J Cancer 2002 (MAP Kinase Signaling System) : Tyrphostin AG1478, an EGFR tyrosine kinase inhibitor, blocks ALP induced MAPK/ERK activation but not EGFR internalization
Prouillet et al., Biochem Pharmacol 2004 (MAP Kinase Signaling System) : The data presented in this study support the conclusion that, in MG-63 osteoblasts ( i ) the increase in ALP activity by flavonols involves a rapid stimulation of ERK activation but also involves the ER, and that ( ii ) the activation of ERK by flavonols occurs most likely downstream of the ERs activation
Mimori et al., J Periodontol 2007 (MAP Kinase Signaling System) : An ERK1/2 inhibitor suppressed ascorbic acid induced ALP and OCN gene expression, whereas Runx2 was not affected in PDL cells
Kim et al., Proc Natl Acad Sci U S A 2008 : Here we show that only alprenolol (Alp) and carvedilol ( Car ) induce beta ( 1 ) AR-mediated transactivation of the EGFR and downstream ERK activation
Rasool et al., Clin Cancer Res 2010 (Carcinoma...) : Both paclitaxel and SLPI overexpression induced ERK activation
Jeong et al., Food Chem Toxicol 2010 : CKS induced enhancement of RUNX2 and ALP was inhibited by treatment with a p38 inhibitor ( SB203580 ) and an ERK inhibitor ( U0126 )